Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.

Abstract

The rate of hypothyroidism as a side-effect of sunitinib in patients with mRCC is significant. Patients with symptomatic hypothyroidism experienced significantly longer PFS, but without difference in OS.